1.39 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to SBFM. SBFM was compared to 535 industry peers in the Biotechnology industry. While SBFM seems to be doing ok healthwise, there are quite some concerns on its profitability. SBFM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
SBFM had negative earnings in the past year.
In the past year SBFM has reported a negative cash flow from operations.
In the past 5 years SBFM always reported negative net income.
In the past 5 years SBFM always reported negative operating cash flow.
1.2 Ratios
SBFM has a better Return On Assets (-19.73%) than 76.82% of its industry peers.
With an excellent Return On Equity value of -24.55%, SBFM belongs to the best of the industry, outperforming 80.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROIC | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SBFM's Gross Margin of 33.33% is fine compared to the rest of the industry. SBFM outperforms 73.46% of its industry peers.
SBFM's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
2. Health
2.1 Basic Checks
SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
SBFM has more shares outstanding than it did 1 year ago.
SBFM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SBFM has an Altman-Z score of -1.14. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
SBFM's Altman-Z score of -1.14 is in line compared to the rest of the industry. SBFM outperforms 56.45% of its industry peers.
There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.14 |
ROIC/WACCN/A
WACC8.7%
2.3 Liquidity
A Current Ratio of 5.00 indicates that SBFM has no problem at all paying its short term obligations.
SBFM has a Current ratio (5.00) which is comparable to the rest of the industry.
A Quick Ratio of 2.66 indicates that SBFM has no problem at all paying its short term obligations.
SBFM's Quick ratio of 2.66 is on the low side compared to the rest of the industry. SBFM is outperformed by 66.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 |
3. Growth
3.1 Past
SBFM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.54%, which is quite impressive.
The Revenue has grown by 44.75% in the past year. This is a very strong growth!
SBFM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 340.61% yearly.
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
3.2 Future
SBFM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.65% yearly.
Based on estimates for the next years, SBFM will show a very strong growth in Revenue. The Revenue will grow by 26.02% on average per year.
EPS Next Y98.37%
EPS Next 2Y41.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.61%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SBFM. In the last year negative earnings were reported.
SBFM is valuated cheaply with a Price/Forward Earnings ratio of 4.13.
Based on the Price/Forward Earnings ratio, SBFM is valued cheaply inside the industry as 99.07% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, SBFM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.13 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SBFM's earnings are expected to grow with 41.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SBFM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SBFM (11/21/2025, 8:00:02 PM)
1.39
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.85%
Inst Owner Change25.57%
Ins Owners0.05%
Ins Owner Change0%
Market Cap6.34M
Revenue(TTM)34.87M
Net Income(TTM)-6.31M
Analysts82.86
Price Target7.14 (413.67%)
Short Float %20.89%
Short Ratio0.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.44%
EPS NY rev (1m)0%
EPS NY rev (3m)-45.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.13 | ||
| P/S | 0.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.25 | ||
| P/tB | 0.27 | ||
| EV/EBITDA | N/A |
EPS(TTM)-51.88
EYN/A
EPS(NY)0.34
Fwd EY24.22%
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS7.97
BVpS5.63
TBVpS5.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.73% | ||
| ROE | -24.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.33% | ||
| FCFM | N/A |
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score4
Asset Turnover1.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 549.76% | ||
| Cap/Sales | 4.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5 | ||
| Quick Ratio | 2.66 | ||
| Altman-Z | -1.14 |
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
EPS Next Y98.37%
EPS Next 2Y41.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%11.64%
Revenue Next Year9.61%
Revenue Next 2Y26.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.81%
OCF growth 3YN/A
OCF growth 5YN/A
SUNSHINE BIOPHARMA INC / SBFM FAQ
Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?
ChartMill assigns a fundamental rating of 4 / 10 to SBFM.
What is the valuation status for SBFM stock?
ChartMill assigns a valuation rating of 4 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Fairly Valued.
How profitable is SUNSHINE BIOPHARMA INC (SBFM) stock?
SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.
What is the financial health of SUNSHINE BIOPHARMA INC (SBFM) stock?
The financial health rating of SUNSHINE BIOPHARMA INC (SBFM) is 6 / 10.
Can you provide the expected EPS growth for SBFM stock?
The Earnings per Share (EPS) of SUNSHINE BIOPHARMA INC (SBFM) is expected to grow by 98.37% in the next year.